To include your compound in the COVID-19 Resource Center, submit it here.

Anthem updates Yescarta, Exondys 51 coverage

Anthem Inc. (NYSE:ANTM) said it will cover newly approved chimeric antigen receptor (CAR) T therapy Yescarta axicabtagene ciloleucel (KTE-C19) from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) for certain patients. The firm also said it will now cover Exondys 51 eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT), reversing its initial

Read the full 525 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE